Although developments in pharmacogenomics have arguably led to an improvement in the efficacy and safety of medicine, there are several ethical and social issues that are being raised. Pharmacogenomics is defined as the study of how genetic variation affects the way an individual responds to medications. This allows for doctors and pharmacists to select for medicines that are well-suited to patients depending on their genetic composition. Despite the benefits of pharmacogenomics, genetic research suffers from racial inequity and lack of informed consent. Clinicians and drug companies must consider these problems when using genetic data and taking part in pharmacogenomics.
If you have any other questions about how to communicate with the FDA or how your past and/or current FDA communications affect you and your business goals, reach out to me on Twitter, LinkedIn, or send me a message here.
I also host a podcast called DarshanTalks, a show that discusses newsworthy FDA issues and how they apply to bringing a product to market – and keeping it there. From patient centricity in clinical trials to the government shutdown to CRISPR and bioethics to why big data is doomed to fail in healthcare, we’ve got quite the list of topics to review! Listen to the podcast on Google Podcasts or on Apple Podcasts.